Jefferies Group Decreased Quest Diagnostics (DGX) Holding By $5.61 Million; Dariohealth (DRIO) Shorts Up By 125.87%

April 17, 2018 - By Lawrence Diaz

DarioHealth Corp. (NASDAQ:DRIO) Logo

Jefferies Group Llc decreased Quest Diagnostics Inc (DGX) stake by 58.8% reported in 2017Q4 SEC filing. Jefferies Group Llc sold 57,273 shares as Quest Diagnostics Inc (DGX)’s stock rose 0.72%. The Jefferies Group Llc holds 40,127 shares with $3.95 million value, down from 97,400 last quarter. Quest Diagnostics Inc now has $13.67B valuation. The stock decreased 0.56% or $0.57 during the last trading session, reaching $100.66. About 719,070 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has risen 1.33% since April 17, 2017 and is uptrending. It has underperformed by 10.22% the S&P500.

Dariohealth Corp (NASDAQ:DRIO) had an increase of 125.87% in short interest. DRIO’s SI was 286,400 shares in April as released by FINRA. Its up 125.87% from 126,800 shares previously. With 706,100 avg volume, 0 days are for Dariohealth Corp (NASDAQ:DRIO)’s short sellers to cover DRIO’s short positions. The SI to Dariohealth Corp’s float is 4.31%. The stock increased 0.57% or $0.01 during the last trading session, reaching $1.76. About 25,008 shares traded. DarioHealth Corp. (NASDAQ:DRIO) has declined 60.40% since April 17, 2017 and is downtrending. It has underperformed by 71.95% the S&P500.

Among 21 analysts covering Quest Diagnostics (NYSE:DGX), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Quest Diagnostics had 69 analyst reports since August 4, 2015 according to SRatingsIntel. The company was maintained on Thursday, July 13 by Credit Suisse. The rating was maintained by Robert W. Baird with “Hold” on Sunday, November 12. On Friday, November 13 the stock rating was maintained by Canaccord Genuity with “Buy”. Mizuho downgraded Quest Diagnostics Incorporated (NYSE:DGX) rating on Wednesday, August 31. Mizuho has “Neutral” rating and $86 target. Bank of America upgraded Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday, July 25 to “Buy” rating. The company was maintained on Monday, March 19 by Canaccord Genuity. The company was maintained on Monday, April 24 by Raymond James. The firm has “Buy” rating by Argus Research given on Wednesday, March 7. The rating was downgraded by Raymond James on Monday, September 25 to “Market Perform”. The stock of Quest Diagnostics Incorporated (NYSE:DGX) has “Neutral” rating given on Thursday, March 16 by Bank of America.

Jefferies Group Llc increased Steel Dynamics Inc (Call) (NASDAQ:STLD) stake by 319,500 shares to 334,400 valued at $14.42 million in 2017Q4. It also upped Weight Watchers Intl Inc New (NYSE:WTW) stake by 17,876 shares and now owns 23,723 shares. Gnc Hldgs Inc (NYSE:GNC) was raised too.

Since January 2, 2018, it had 0 buys, and 13 selling transactions for $30.90 million activity. Another trade for 106,840 shares valued at $11.43M was sold by RUSCKOWSKI STEPHEN H. Doherty Catherine T. had sold 21,294 shares worth $2.21 million. 5,122 shares valued at $517,322 were sold by Davis J. E. on Friday, March 2. Shares for $416,928 were sold by PREVOZNIK MICHAEL E on Friday, March 2. On Thursday, March 8 the insider Cohen Jon R sold $8.72 million. Klug Robert A sold $119,932 worth of Quest Diagnostics Incorporated (NYSE:DGX) on Friday, February 23.

Investors sentiment decreased to 0.92 in Q4 2017. Its down 0.06, from 0.98 in 2017Q3. It is negative, as 52 investors sold DGX shares while 192 reduced holdings. 67 funds opened positions while 158 raised stakes. 115.48 million shares or 1.22% less from 116.90 million shares in 2017Q3 were reported. Pacad Inv has invested 0.02% in Quest Diagnostics Incorporated (NYSE:DGX). Goldman Sachs Gp invested in 1.74 million shares or 0.04% of the stock. 263,169 were accumulated by Gotham Asset Llc. Amf Pensionsforsakring holds 0.19% or 200,515 shares in its portfolio. Adage Prns Gp Ltd holds 27,300 shares or 0.01% of its portfolio. Philadelphia Com has invested 0.11% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Tower Research Lc (Trc) holds 0% in Quest Diagnostics Incorporated (NYSE:DGX) or 349 shares. Bluecrest Mngmt stated it has 10,523 shares or 0.03% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) owns 107,993 shares. First Manhattan Co holds 112 shares or 0% of its portfolio. Northwestern Mutual Wealth Mgmt Com accumulated 0% or 4,083 shares. The California-based Investors has invested 0.04% in Quest Diagnostics Incorporated (NYSE:DGX). Wellington Mngmt Group Inc Llp holds 0.01% or 241,226 shares. California State Teachers Retirement Systems reported 245,030 shares stake. Brandywine Glob Inv Mgmt Limited Liability Corporation invested 0.07% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX).

Analysts await Quest Diagnostics Incorporated (NYSE:DGX) to report earnings on April, 19 before the open. They expect $1.53 earnings per share, up 15.04% or $0.20 from last year’s $1.33 per share. DGX’s profit will be $207.75 million for 16.45 P/E if the $1.53 EPS becomes a reality. After $1.38 actual earnings per share reported by Quest Diagnostics Incorporated for the previous quarter, Wall Street now forecasts 10.87% EPS growth.

DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing clients with laboratory-testing capabilities using smart phones and other mobile devices. The company has market cap of $29.01 million. The Company’s flagship product is Dario, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It currently has negative earnings. The firm is also pursuing patent applications in various jurisdictions covering the specific processes related to blood glucose level measurement, as well as various general methods of rapid tests of body fluids using mobile devices and cloud services.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: